FDA ap­proves first sub­cu­ta­neous ver­sion of block­buster IBD drug in­flix­imab

The FDA on Sun­day ap­proved Cell­tri­on’s Zym­fen­tra (in­flix­imab-dyyb), which is the first sub­cu­ta­neous ver­sion of the block­buster bi­o­log­ic, as main­te­nance ther­a­py for in­flam­ma­to­ry bow­el dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER